French companies Cerenis Therapeutics, which is developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and other metabolic diseases, and Groupe Novasep, a supplier of manufacturing solutions to the life sciences industries, have received government funding of 10.7 million euros ($13.7 million) through France's innovation agency (OSEO) to finance the development of CER-001, a Cerenis HDL mimetic. The OSEO operates under the authority of the Ministry of Economy, Finance and Employment, and the Ministry for Higher Education and Research.
CER-001 represents a promising new approach in the fight against atherosclerotic cardiovascular disease and has shown strong preclinical efficacy in promoting reverse lipid transport, a natural cardioprotective mechanism by which excess lipids are removed from peripheral tissues and from within atherosclerotic plaques then taken to the liver for elimination. The program is currently in Phase 1 clinical development for the treatment of post-acute coronary syndrome patients.
The funding from the OSEO will allow the further progression of Cerenis' novel HDL therapy for orphan disease applications, which represent a large area of unmet need and the potential for an accelerated development pathway.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze